SCIENTIFIC OPINION

Inability to assess the safety of vitamin C-enriched yeast added for nutritional purposes as a source of vitamin C in food supplements and the bioavailability of vitamin C from this source, based on the supporting dossier

Scientific Statement of the Panel on Food Additives and Nutrient Sources added to Food (ANS)

(Question No EFSA-Q-2005-194)

Adopted on 5 June 2009

PANEL MEMBERS

---

1 For citation purposes: Scientific Statement of the Panel on Food Additives and Nutrient Sources added to Food on the inability to assess the safety of vitamin C-enriched yeast added for nutritional purposes as a source of vitamin C in food supplements and the bioavailability of vitamin C from this source, based on the supporting dossier following a request from the European Commission. The EFSA Journal (2009) 1133, 1-6.
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The European Community legislation lists nutritional substances that may be used for nutritional purposes in certain categories of foods as sources of certain nutrients.

The Commission has received a request for the evaluation of vitamin C-enriched yeast added for nutritional purposes to food supplements. The relevant Community legislative measure is:


TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission asks the European Food Safety Authority to provide a scientific opinion, based on its consideration of the safety and bioavailability of vitamin C-enriched yeast added for nutritional purposes to food supplements.
STATEMENT

1. Introduction

Following a request from the European Commission to the European Food Safety Authority (EFSA), the Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide a scientific opinion on the safety of vitamin C-enriched yeast added for nutritional purposes as a source of vitamin C in food supplements and on the bioavailability of vitamin C from this source.

2. Summary of the information provided in the supporting dossier on vitamin C-enriched yeast

Vitamin C-enriched yeast is derived from cultures of specified strains of *Saccharomyces cerevisiae* grown in the presence of vitamin C. Fermentation takes place at a specified temperature and pressure for defined periods of time. This is followed by increasing the temperature to kill the yeast. The cell wall is ruptured enzymatically to release the contents which are then spray dried.

The petitioner has provided some general information on the manufacturing process, but no details on the procedures used to produce vitamin C-enriched yeast are provided.

According to the petitioner, vitamin C in vitamin C-enriched yeast is naturally integrated by the growing yeast into its own structure and occurs therefore, in the way vitamin C would be present in any food material.

The petitioner states that during fermentation in the presence of vitamin C, a specific strain of *Saccharomyces cerevisiae* incorporates vitamin C into ‘biological complexes’ the metabolic fate and the biological distribution of which are similar to those of other sources of vitamin C in the diet.

The petitioner states that “the integration will be chemically multi-formatted by the organism and therefore, its chemical name, formula, chemical family and CAS Registry Number is undefined”. Further details on the chemical characterisation of the fermentation products to demonstrate that the expected complexes of the vitamin C are present in the enriched yeast were not provided.

Comparative Fourier Transform Infrared (FTIR) spectra of the starter yeast, vitamin C, vitamin C-enriched yeast and a simple mixture of yeast and vitamin C have been provided.

Vitamin C-enriched yeast is described as a brown amorphous hygroscopic powder with a slight yeast/citrus odour, soluble in water at 20°C.

According to the petitioner, vitamin C is present at 25% of the source. The remaining 75% is made up of enzymatically ruptured yeast cells.

The petitioner also provides microbiological specifications. Specifications for lead, mercury, cadmium and arsenic were not provided.

The petitioner states that, depending on the type of supplement, in capsule form the use level of vitamin C derived from vitamin C-enriched yeast varies between 6.7 µg and 30 µg vitamin C. No information is provided on the use level of vitamin C derived from vitamin C-enriched yeast.
yeast in tablets. The petitioner only informs that vitamin C is available in supplements at many levels up to 1000 mg.

No data were provided on the bioavailability of vitamin C from vitamin C-enriched yeast or on the safety of the source.

3. Assessment

The Panel notes that *Saccharomyces cerevisiae* has a qualified presumption of safety (EFSA, 2008) but considers that this presumption of safety might not be applicable to the specific conditions of culture of the yeast in the presence of a high quantity of vitamin C.

According to the petitioner, fermentation in the presence of vitamin C within eukaryotic cells will produce vitamin C/yeast complexes, similar to those of other sources of vitamin C in the diet.

According to the petitioner, from the comparative FTIR spectra it can be deduced that vitamin C is integrated in a ‘biological complex’ with yeast. The Panel considers that the FTIR spectra provided do not demonstrate the existence of such complexes.

According to the petitioner, vitamin C from vitamin C-enriched yeast is safe. Although not explicitly stated in the dossier, the argument for the safety of vitamin C-enriched yeast appears to be based on vitamin C being a normal constituent of the diet, and the long history of use of *Saccharomyces cerevisiae* in fermented food and beverages. The assumption is that, provided there is no overload of the normal metabolic pathways, fermentation within eukaryotic cells will produce vitamin C complexes, the metabolic fate and the biological distribution of which are similar to those of other sources of vitamin C in the diet.

The Panel notes that the petitioner has insufficiently chemically characterised the product.

The Panel also notes that it was not possible to assess the bioavailability of vitamin C from vitamin C-enriched yeast since neither data nor suitable supporting references were provided.

The Panel further notes that neither safety data nor suitable supporting references were provided to support the assumption of safety of vitamin C-enriched yeast.

**CONCLUSIONS**

The Panel concludes that due to the lack of an appropriate dossier supporting the use of vitamin C-enriched yeast in food supplements, the bioavailability of vitamin C from vitamin C-enriched yeast and the safety of vitamin C-enriched yeast cannot be assessed.

**Key words:**

Food supplements, vitamin C, ascorbic acid, yeast-transformed vitamin C, vitamin C-enriched yeast
Inability to assess the safety of vitamin C-enriched yeast as a source of vitamin C in food supplements

DOCUMENTATION PROVIDED TO EFSA


REFERENCES


ACKNOWLEDGEMENTS

Inability to assess the safety of vitamin C-enriched yeast as a source of vitamin C in food supplements

GLOSSARY / ABBREVIATIONS

ANS  Panel on Food Additives and Nutrient Sources added to Food
CAS  Chemical Abstracts Service
EC   European Commission
EFSA  European Food Safety Authority
FTIR  Fourier Transform Infrared